Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2026)
Silence Therapeutics' (SLN) quarterly Income from Continuing Operations came in at 14957000.0 in Q1 2026, up 47.57% year-on-year from 10135221.01 in Q1 2025, and down 16.42% quarter-over-quarter from 12848000.0 in Q4 2025.
Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Silence Therapeutics has disclosed Income from Continuing Operations across 3 years of filings, most recently posting 14957000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 14957000.0, up 47.57% year-over-year; the trailing twelve-month figure through Mar 2026 was 76117000.0 (down 6.42% YoY), and the FY2025 annual result was 89690000.0, down 97.95% from the prior year.
- Income from Continuing Operations came in at 14957000.0 for Q1 2026 at Silence Therapeutics, down from 12848000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 12302000.0 in Q4 2024 to a low of 35544000.0 in Q3 2024.
- The 3-year median for Income from Continuing Operations is 19755000.0 (2024), against an average of 16661777.78.
- Across the five-year window, Income from Continuing Operations tumbled 1134.0% in 2025 and surged 47.57% in 2026, its largest moves.
- Silence Therapeutics' Income from Continuing Operations stood at 12302000.0 in 2024, then slumped by 204.44% to 12848000.0 in 2025, then decreased by 16.42% to 14957000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 14957000.0 (Q1 2026), 12848000.0 (Q4 2025), and 20958000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Silence Therapeutics | 945.86 Mn | 875.79 Mn | 411,000.00 | -14.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.96 Mn |
| Dec 31, 2025 | -12.85 Mn |
| Sep 30, 2025 | -20.96 Mn |
| Jun 30, 2025 | -27.35 Mn |
| Mar 31, 2025 | -28.53 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Sep 30, 2024 | -35.54 Mn |
| Jun 30, 2024 | -19.76 Mn |
| Mar 31, 2024 | -2.31 Mn |